EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation

Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, has achieved high clinical response rates in patients with non–small cell lung cancers (NSCLCs). However, over time, most tumors develop acquired resistance to EGFR-TKIs, which is...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Teppei, Azuma, Koichi, Muta, Emi, Kim, Jintaek, Sugawara, Shunichi, Zhang, Guang Lan, Matsueda, Satoko, Kasama-Kawaguchi, Yuri, Yamashita, Yuichi, Yamashita, Takuto, Nishio, Kazuto, Itoh, Kyogo, Hoshino, Tomoaki, Sasada, Tetsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818324/
https://www.ncbi.nlm.nih.gov/pubmed/24223798
http://dx.doi.org/10.1371/journal.pone.0078389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818324/
https://www.ncbi.nlm.nih.gov/pubmed/24223798
http://dx.doi.org/10.1371/journal.pone.0078389

Ejemplares similares